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ABSTRACT 
Heart failure (HF) is a complex clinical syndrome in which structural / functional 
myocardial abnormalities result in symptoms and signs of hypoperfusion and/or pulmonary 
or systemic congestion at rest or during exercise. More than 80% of deaths in patients with 
HF recognize a cardiovascular cause, with most being either sudden cardiac death (SCD) 
or death caused by progressive pump failure. Risk stratification of SCD in patients with HF 
represents a clinical challenge. This review will give an update of current strategies for 
SCD risk stratification in HF.  
 
Introduction 
Heart failure is a complex clinical 
syndrome with structural abnormality or a 
myocardial which resulted in signs and 
symptoms of hypoperfusion and/or 
pulmonary or systemic congestion during 
rest or activity.1,2 
Sudden cardiac death is defined as 
death caused by unexpected stop in 
blood circulation that occurs within one 
hour from the start of symptoms or during 
sleep.3 In the majority of cases, sudden 
cardiac death is triggered by arrythmia 
(e.g. ventricle tachycardia, ventricle 
fibrillation), although pulseless electrical 
activity (PEA) is recently reported as the 
cause of sudden cardiac death.4 
Risk stratification for sudden 
cardiac death in heart failure patients 
with reduced ejection fraction still 
becomes a clinical challenge. Recent 
guideline provides an algorithm 
according to left ventricle ejection fraction 
in which this parameter is considered as 
the only parameter to identify high risk 
patients.5 Nevertheless, current 
approaches cannot be used to stratify the 
population and risk spectrum with high 
accuracy. 
 
Pathophysiology of Sudden Cardiac 
Death 
The mechanism of sudden cardiac 
death in heart failure patients with 
reduced ejection fraction (HFrEF) is 
complex in nature and requires a chain of 
interaction between transient events with 
pathological basic substrate which 
triggers electric instability (Figure 1).
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Figure 1. Anatomical substrate and pathophysiology of sudden cardiac death in heart failure with 
reduced ejection fraction. PVCs: premature ventricular complex; QT: QT interval6 
 
In ischemic cardiomyopathy, 
sudden cardiac death is related to 
previously infarcted myocardial region 
near a thick scar that forms from time to 
time. Residual endomyocardial fiber can 
persist because the blood gives nutrition 
to this area in the ventricle (e.g. through 
retrograde perfusion through left atrial 
vein, retrograde perfusion through 
sinusoidal tract, or through oxygen 
diffusion from blood flow in ventricle 
through myocardium).7 In patients with 
systolic dysfunction that occurs after 
myocardial infarction, sudden cardiac 
death caused by non-arrythmia often 
occurs within the first hour to six weeks 
and is related to a mechanical 
complication of myocardial infarction 
itself (e.g. rupture in the left ventricle wall, 
rupture in the interventricular septum and 
acute mitral regurgitation).8This showed 
that the proportion of sudden cardiac 
death caused by arrythmia and non-
arrythmia to be the same after 1 month 
from myocardial infarction. This reason 
explains from the current guideline where 
implantable cardioverter defibrillator 
(ICD) is recommended in 40 days post 
myocardial infarction.9,10 In non-ischemic 
cardiomyopathy, the ventricular 
myocardium has multiple fibrosis area 
without significant scar.11 This finding 
explains why reentry only involves 40% 
of ventricular arrythmia mechanism in 
patients with non-ischemic 
cardiomyopathy, while the rest is caused 
by triggered activity process (for example 
early after depolarizations and delayed 
after depolarizations).12,13 
The main mechanism of sudden 
cardiac arrest in heart failure patients 
with preserved ejection fraction (HFpEF) 
seems to be related to myocardial 
fibrosis which causes changes in regional 
conductive pattern and become the area 
of reentry.14 Furthermore, ischemia is 
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thought to be a contributor that needs 
further investigation on ventricular 
arrythmia in HFpEF patients.15 Without 
considering the cause of heart failure and 
the value of left ventricular ejection 
fraction, in patients with advanced heart 
failure, arrythmia is triggered primarily by 
heart pump failure where around 60% of 
patients had severe bradyarrhythmia or 
electromechanical dissociation as the 
primary cause of sudden cardiac death.16 
Table 1. Sudden cardiac death risk factor  in patients with  HFrEF 
Patient and Family History 
- Previous Myocardial Infarction event 
- Family history of sudden cardiac death 
- Syncope without exact causes 
Electrocardiography  
- QRS complex duration 
- T-wave alternans 
- Signal averaged ECG 
Autonomic function 
- Heart rate variability 
- Blood flow turbulence 
Electrophysiology findings 
- Easily triggered Ventricular arrhytmia 
- Extensive low voltage / abnormal signals on electroanatomic 
mapping 
- Broad scar area in mid-epicardium 
- Multiple ventricular tachycardia morphology 
Echocardiography findings 
- Left Ventricle ejection fraction 
- Ventricular disynchronized 
- finding on speckle tracking 
- Mechanical Dispertion 
Cardiac MRI 
- Late gadolinium enhancement 
- T1 mapping 
Myocardial Sympathetic Innervation Imaging 
- Heart to mediastinal ratio 
Biomarker 
- Natriuretic peptide 
- High sensitive troponin 
- Soluble ST2 
Genetic 
- Lamin A/C Mutation 
- Desmin Mutation 
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Risk Stratification of Sudden 
Cardiac Failure in HFrEF 
Even though several risk factors on 
sudden cardiac death has been known 
and was thought to play a role in HFrEF 
(Table 1), risk stratification to determine 
which patient is beneficial to ICD 
placement as an effort of primary 
prevention to sudden cardiac death still 
arises a question. 
 
Risk Stratification of Sudden 
Cardiac Death in HFpEF 
In a recent study involving HFpEF 
population, sudden cardiac death is 
reported to be one of the most common 
cause of death. In CHARM (Candesartan 
in Heart Failure-Assessment of 
Reduction in Mortality and Morbidity) 
study, it was shown that sudden cardiac 
death is found in 28% of death.17 Similar 
to this study, 26% of all cause of death in 
I-PRESERVE (Irbesartan in Patients with 
Hearth Failure and Preserved Ejection 
Fraction) study is related to sudden 
cardiac death.18 
In daily clinical practice, risk 
evaluation to sudden cardiac death in 
patients with HFpEF specifically has still 
been a challenge, both from the 
variability of phenotype and high 
percentage of death due to non-
cardiovascular. Table 2 described the 
risk factor in patients with HFpEF on 
sudden cardiac death. 
 
Conclusion 
Even though pharmacological and 
electrical therapy has advanced, sudden 
cardiac death is still the most common 
cause of mortality in patient with HFrEF. 
A pilot study has shown that left ventricle 
ejection fraction and ischemic process 
have been predictors to sudden cardiac 
death.  
Nevertheless, epidemiological 
changes on sudden cardiac death require 
identification on risk stratification in the 
population. In regard to this, current 
imaging technique, ECG findings and 
genetic test can be used to improve the 
identification of individuals with high risk 
stratification which should be beneficial 
for specific approach to prevent sudden 
cardiac death (Figure 2). 
On the other hand, patients with 
HFpEF also have high prevalence in 
sudden cardiac death. For this 
population, increasing the understanding 
of pathophysiological pattern of sudden 
cardiac death should improve risk 
stratification of sudden cardiac death.
 
Table 2. Sudden cardiac death  risk factor  in patients with  HFpEF 
History  
- Age 
- Male 
- Diabetes Mellitus on insulin 
- Previous Myocardial Infarction 
Electrocardiography 
- Left Bundle Branch Block 
Biomarker 
- Natriuretic Peptide 
Bagaswoto, 2019    ACI (Acta Cardiologia Indonesiana) Vol.5 No.1(P):1-7  
5 
 
 
Figure 2. Risk stratification of sudden cardiac death in HFrEF patients 
EF: Ejection fraction, VTs: Sustained ventricular tachycardias, ICD: Implantable cardioverter 
defibrillator, CMR: Cardiac magnetic resonance, H/M ratio: Heart/mediastinum ratio, GLS: Global 
longitudinal strain 
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